Evidence map›Paper›PMID 29731630›Full record

ArticleInternational journal of nanomedicine2018

Peptide-functionalized quantum dots for potential applications in the imaging and treatment of obesity.

Ntevheleni Thovhogi, Nicole Remaliah Samantha Sibuyi, Martin Opiyo Onani, Mervin Meyer, Abram Madimabe Madiehe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. A Review of in vivo Toxicity of Quantum Dots in Animal Models.International journal of nanomedicine · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Polymeric Carriers for Controlled Drug Delivery in Obesity Treatment.Trends in endocrinology and metabolism: TEM · 2019
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ntevheleni ThovhogiDepartment of Science and Technology (DST)/Mintek Nanotechnology Innovation Centre, Biolabels Unit, Department of Biotechnology.
Nicole Remaliah Samantha SibuyiDepartment of Science and Technology (DST)/Mintek Nanotechnology Innovation Centre, Biolabels Unit, Department of Biotechnology.
Martin Opiyo OnaniOrganometallics and Nanomaterials, Department of Chemistry, University of the Western Cape, Bellville, South Africa.
Mervin MeyerDepartment of Science and Technology (DST)/Mintek Nanotechnology Innovation Centre, Biolabels Unit, Department of Biotechnology.
Abram Madimabe MadieheDepartment of Science and Technology (DST)/Mintek Nanotechnology Innovation Centre, Biolabels Unit, Department of Biotechnology.
Mintek · ZAUniversity of the Western Cape · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity is a worldwide epidemic affecting millions of people. The current pharmacological treatment of obesity remains limited and ineffective due to drugs' undesirable side effects. Hence, there is a need for novel or improved strategies for long-term therapies that will help prevent the disease progression into other chronic diseases. Nanotechnology holds the future for the treatment of obesity because of its versatility, as shown by improved drug efficiency and safety in cancer clinical trials. Nano-based drug delivery systems could potentially do the same for obesity through targeted drug delivery. This study investigated the use of peptide-functionalized quantum dots (QDs) for the imaging of prohibitin (PHB)-expressing cells in vitro and in diet-induced obese rats, which could potentially be used as nanocarriers of antiobesity drugs.

methodsCadmium (Cd)-based QDs were functionalized with an adipose homing peptide (AHP) and injected intravenously into lean and obese Wistar rats. Biodistribution of the QDs was analyzed by an IVIS

resultsAHP-QD625 accumulated significantly in PHB-expressing cells in vitro when compared with non-PHB-expressing cells. In vivo data indicated that QD625 accumulated mainly in the reticuloendothelial system (RES) organs, while the AHP-QD625 accumulated mostly in the white adipose tissues (WATs).

conclusionAHP-functionalized QDs were successfully and selectively delivered to the PHB-expressing cells in vitro (Caco-2 and MCF-7 cells) and in the WAT vasculature in vivo. This nanotechnology-based approach could potentially be used for dual targeted drug delivery and molecular imaging of adipose tissues in obese patients in real time.

Indexed as

Adipose TissueAnimalsAnti-Obesity AgentsCaco-2 CellsCadmiumCHO CellsCricetulusDiet, High-FatDrug Delivery SystemsHumansMaleMicroscopy, FluorescenceMononuclear Phagocyte SystemObesityPeptidesProhibitinsAnti-Obesity AgentsCadmiumPeptidesPHB protein, humanPhb protein, ratProhibitinsRepressor Proteinsadipose homing peptidedrug deliverynanotechnologyprohibitinwhite adipose tissue

Identifiers

PMID29731630
PMCPMC5927349
OpenAlexW2800423573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.